drugset / Trial / NCT00859040
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase 2
Completed
34 enrolled
Patrick Y. Wen, MD
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabCedars-Sinai Medical Center · collabDuke University · collabMassachusetts General Hospital · collabMemorial Sloan Kettering Cancer Center · collabNorthwestern University · collabNovartis · collabWake Forest University Health Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those other research studies suggests that SOM230C may help to stop the growth of meningiomas.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-12
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pasireotide | Other / unclassified | 60 mg | Intramuscular |